Biodexa Pharmaceuticals (BDRX) Cash & Equivalents (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Cash & Equivalents of $11.4 million for Q4 2025, up 429.91% on a YoY basis from $2.1 million in Q4 2024, and up 110.83% sequentially from $5.4 million in Q2 2025.
Biodexa Pharmaceuticals (BDRX) Cash & Equivalents (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 13 years of Cash & Equivalents data on file, last reported at $11.4 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 429.91% year-over-year to $11.4 million; the trailing twelve-month figure through Dec 2025 stood at $11.4 million (up 429.91% YoY), and the FY2025 full-year result was $11.3 million, up 425.27% from the prior year.
- Cash & Equivalents improved to $11.4 million in Q4 2025, from $5.4 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $13.6 million in Q4 2021 to a low of $2.1 million in Q4 2024.
- A 5-year average of $7.0 million and a median of $6.5 million in 2024 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents tumbled 75.46% in 2022 and soared 429.91% in 2025, its largest moves.
- Tracing BDRX's Cash & Equivalents over 5 years: stood at $13.6 million in 2021, then tumbled by 75.46% to $3.3 million in 2022, then jumped by 122.79% to $7.4 million in 2023, then slumped by 71.09% to $2.1 million in 2024, then soared by 429.91% to $11.4 million in 2025.
- Business Quant data shows BDRX's Cash & Equivalents at $11.4 million in Q4 2025, $5.4 million in Q2 2025, and $2.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | 11.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.35 Mn |
| Jun 30, 2025 | 5.38 Mn |
| Dec 31, 2024 | 2.14 Mn |
| Jun 30, 2024 | 6.38 Mn |
| Dec 31, 2023 | 7.41 Mn |
| Jun 30, 2023 | 6.54 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Jun 30, 2022 | 8.09 Mn |
| Dec 31, 2021 | 13.56 Mn |
| Jun 30, 2021 | 5.88 Mn |
| Dec 31, 2020 | 9.96 Mn |
| Jun 30, 2020 | 5.37 Mn |
| Dec 31, 2019 | 14.05 Mn |
| Jun 30, 2019 | 11.55 Mn |
| Dec 31, 2018 | 3.01 Mn |
| Jun 30, 2018 | 5.61 Mn |
| Dec 31, 2017 | 17.53 Mn |
| Jun 30, 2017 | 7.90 Mn |
| Dec 31, 2016 | 21.89 Mn |
| Jun 30, 2016 | 10.38 Mn |